SCHEMBL7595694

SCHEMBL7595694

COc1ccc(S(=O)(=O)NC(Cc2cccnc2)C(=O)N2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AVPR1B P47901 1/20 0.48
CHRM1 P11229 1/20 0.47
PLG P00747 5/20 0.46
F10 P00742 3/20 0.46
HPN P05981 1/20 0.46
KMT2A Q03164 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
ALDH1A1 P00352 3/20 0.45
USP2 O75604 1/20 0.45
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
F2 P00734 2/20 0.45
PLAU P00749 2/20 0.45
ST14 Q9Y5Y6 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7594737 0.80 GFER (0.54) CHRM1LMNA
SCHEMBL7594697 0.75 CHRM1 (0.53) CHRM1POLBNAMPT
SCHEMBL7598387 0.75 CHRM1 (0.52) CHRM1KMT2A
SCHEMBL7445017 0.73 ITGB3 (0.48) KMT2ATDP1PDE4APDE4BPDE4C
SCHEMBL7600340 0.73 CACNA2D1 (0.45) KMT2ATDP1PDE4APDE4BPDE4C
SCHEMBL4778905 0.72 CHRM1 (0.60) CHRM1KMT2APLAUNAMPT
SCHEMBL7425436 0.68 PKM (0.82) KMT2AALDH1A1PDE4APDE4BPDE4C
SCHEMBL31350913 0.68 RXFP1 (0.71) KMT2ATDP1ALDH1A1USP2KDM4E
SCHEMBL31350736 0.68 FNTA (0.76) CHRM1KMT2AALDH1A1USP2KDM4E
SCHEMBL6368043 0.67 TP53 (0.58) KMT2ATDP1ALDH1A1USP2PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020119979-A1 Acyclic compounds and methods for treating multidrug resistance PROCTER & GAMBLE COMPANY, THE 2002-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119979-A1 Acyclic compounds and methods for treating multidrug resistance ABCC1, ABCB1, ABCB11 AVPR1B 919/4885CHRM1 3787/4885PLG 3124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.